Related Experiment Video
Updated: Jun 17, 2026
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
Risk of pN2/3 Understaging in Sentinel Node-Positive ER+/HER2- Breast Cancer: A Composite Clinicopathologic Score for
Soong June Bae1, Janghee Lee2, Sung-Im Do3
1Department of Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
Background:
Adjuvant treatment decisions in ER+/HER2- breast cancer depend on accurate distinction between pN1 and pN2/3 disease. As sentinel lymph node biopsy (SLNB) increasingly replaces axillary lymph node dissection (ALND), patients with apparent pN1 disease may be understaged. We evaluated preoperative imaging and developed a composite risk score to identify patients for whom completion ALND might be omitted.
Methods:
We retrospectively analyzed 160 ER+/HER2- patients with 1-3 positive sentinel nodes who underwent completion ALND after upfront surgery. Four imaging modalities were assessed for pN2/3 (≥4 positive nodes). A five-item composite score (SLN ≥ 2, lymphovascular invasion, tumor ≥2 cm, Ki-67 ≥20%, multifocality; range 0-5) underwent bootstrap validation and decision curve analysis (DCA).
Results:
All four preoperative imaging modalities failed to predict pN2/3 under-staging (NPV 80-86%; all p ≥ 0.885). Overall, 17.5% harbored true pN2/3 on completion ALND. Low-risk patients (score ≤1; 32% of cohort) had a pN2/3 rate of only 3.9% (NPV 96.1%; sensitivity 92.9%) versus 23.9% in high-risk patients (p = 0.0015). DCA showed net benefit over a treat-all strategy across clinically relevant thresholds, corresponding to ~14 fewer unnecessary ALNDs per 100 patients.
Conclusions:
Preoperative imaging showed limited sensitivity for pN2/3 under-staging and should not alone guide omission of completion ALND. A five-item composite score identified a low-risk subgroup (NPV 96.1%) in whom completion ALND might be omitted without compromising monarchE or RxPONDER decisions; prospective external validation is required before routine adoption.